Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06364124
Status:
RECRUITING
Last Update Posted:
2024-05-22
First Post:
2024-04-01
Brief Title:
Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction
Sponsor:
Beijing Luhe Hospital
Organization:
Beijing Luhe Hospital
Study Overview
Official Title:
Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction A Single-centerRandomizedOpen-label Trial
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Acute ST-segment elevation myocardial infarction STEMI is a common manifestation of cardiovascular emergencies Percutaneous coronary intervention PCI and guideline-recommended pharmacotherapy have reduced mortality rates associated with STEMI but the incidence of recurrent ischemic events particularly early ischemic events remains high Current research suggests that low-density lipoprotein cholesterol LDL-C levels not meeting guideline-recommended levels and inflammation are closely related to early recurrent ischemic events Evolocumab a proprotein convertase subtilisinkexin type 9 PCSK9 inhibitor rapidly and effectively reduces LDL-C levels and suppresses inflammation Long-term use in patients with acute coronary syndromes can reverse atherosclerosis and improve prognosis However data on its use in STEMI patients are limited particularly regarding the cardioprotective effects of preoperative administration of 420mg evolocumab subcutaneous injection This study aims to evaluate the effects of administering evolocumab 420mg before emergency PCI on lipid profiles inflammatory markers myocardial injury and short-term prognosis in STEMI patients through a single-center randomized open-label study It aims to provide theoretical evidence for further reducing the risk of recurrent cardiovascular events in STEMI and identifying more optimized treatment strategies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None